Friday, 20 Oct 2017

You are here

The RheumNow Week in Review - 6 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.

  1. Study of 16207 RA patients >65yrs shows non-serious infection rate of 47.5/100PY; increased 20% by steroid use.Infx common in RA https://t.co/Pj4i5ulitL
  2. Rules for Drug Cessation with Infection 
  3. 241 patients with Clinically suspect arthralgia - Positive Serology increases RA risk: CCP HR 8.5; RF 5.1; CarbP Ab 3.9; RF+CCP+ has PPV 67% https://t.co/tjxoN4xAMR
  4. Frequence of Secondary Sjogrens is 20% in RA and 14% in SLE - with a >15 to 1 female to male ratio https://t.co/61CxwzrOve
  5. Lower RA dz activity & remission assoc w/ lower serious infection rates! Inflammation (not drugs) drives infx risk https://t.co/QXMzeHSdUi
  6. 107 JIA pts followed for 3 yrs on Biologics- 25% (35) had Serious/Opportunistic infx. range 10.6-14.8/100py https://t.co/8kad5PmLKR
  7. In 19 RCTs, 6194 RA pts received tofacitinib for 19406 pt-Yrs & 19 developed lymphoma (SIR 2.62) or 1:1000 PY risk https://t.co/UuWEQmGEGB
  8. 2016 US Top selling drugs: Humira $13.6 billion, Enbrel $7.4 billion, Remicade $5.3 billion, Lyrica $4.4B,RTX $3.9B
  9. Idiopathic arthralgias pts with no US synovitis have negative predictive value 89% for developing inflam arthritis https://t.co/Hw9zThoCCw
  10. RA RCT Inclusion of FM or Depression pts or pts on SSRI had 10% less ACR20 & 1/2 LDAS responses, more W/D & AE https://t.co/TaXhrLsxPU
  11. In 7-15% PSA precedes Pso;In remainder, median time from PSO dx to PsA is 7-8yrs. <75% get PsA w/in 10-15 yrs of PsO
  12. IBD Associated with Increased risk of Autoimmune and Inflammatory Diseases
  13. Patterns of Biologic Use During Autoimmune Pregnancy 
  14. Alcohol Related Deaths Increased in Psoriasis

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

13 October 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!

The Big Need - NPs and PAs

Despite being one of the most satisfying of medical subspecialties, the number of U.S. rheumatologists is about to sharply decline.  These data were presented at the 2016 ACR meeting, where it was shown that the estimated total number of U.S. rheumatologists in in 2015 was 4,933 and is projected decrease to 3,645 by 2025. During this declining clinical supply, there will be a 138% increase in demand from 6,155 to 8,184 by 2030.

Arthritis Burden over $303 Billion Annually in U.S.

Arthritis of all types in the U.S. carried an economic burden of $303.5 billion in 2013, nearly 1% of the gross domestic product that year, according to a CDC analysis.

29 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses regulatory actions by NICE and FDA, higher death rates in RA and psoriasis, increased risk of RA with Asthma, rising numbers for OA, RA, and STDs.

22 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses survey results on membranous nephritis and patient perceptions of steroids, nonadherence, celebrity arthritis and IgG4 treatment.